

31 December 2025

RECKITT COMPLETES DIVESTMENT OF ESSENTIAL HOME

(London, UK, 31 December 2025): Following the announcement on 18 July 2025, Reckitt Benckiser Group plc ("Reckitt") is pleased to announce that it completed the divestment of its Essential Home business to Advent International, L.P. ("Advent") on 31 December 2025. Reckitt retains an interest in Essential Home through a 30% equity stake in Advent's acquisition vehicle.

As previously communicated and subject to shareholder approval, Reckitt expects to return excess capital from the divestment to shareholders. A circular and notice of general meeting setting out details of the proposed c.US\$2.2 billion special dividend and associated share consolidation is expected to be issued on or around 7 January 2026. This return is in addition to Reckitt's ongoing share buyback programme and ordinary dividend policy.

Commenting on the divestment, Kris Licht, Reckitt Chief Executive Officer said:

"The completion of the divestment of Essential Home is a major step forward in our strategy, moving Reckitt towards becoming a simpler, more effective world-class consumer health and hygiene company focused on a core portfolio of high-growth, high-margin Powerbrands. I want to thank all our Essential Home colleagues for their contributions to Reckitt and wish them well for the future."

Notes:

Essential Home will be excluded from Reckitt's Like-for-Like Net Revenue growth percentages for FY 2025 financial reporting, in line with the Group's published Alternative Performance Measure (APM) policies for disposals completed during the year.

Enquiries:

Investors and Analysts:

Nick Ashworth	+44 (0)7408 812350
Jon Bone	+44 (0)7408 811493

Media:

Anna Davies, Corporate Affairs	+44 (0)7408 861689
Charlie Armitstead, FTI Consulting	+44 (0)7703 330269

About Reckitt:

We make the products people trust to care for the ones they love. We are home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepisils, Vanish and Veet. Consumers are at the heart of everything we do. By creating innovative, science-backed solutions, we support people every day to live healthier lives.

Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products we make. Through our actions, we expand access to healthcare, education and economic opportunities. We support the planet by reducing waste, conserving resources and driving sustainable innovation.

We believe good health starts at home. With every action we take, we strive to make our consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future.

*Reckitt is the trading name of the Reckitt group of companies

Cautionary note concerning forward-looking statements

This announcement contains statements which are, or may be deemed to be, "forward looking statements" which are prospective in nature. All statements other than statements of historical fact are forward-looking statements.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside Reckitt's control.

These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, Reckitt expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Reckitt's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

LEI: 5493003JFSMOJG48V108

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DISBFLFXELFFBZ